首页 | 本学科首页   官方微博 | 高级检索  
     

利他唑酮干混悬剂体内抗菌作用研究
引用本文:朱珍真 陈贞 郎丽巍 王红艳 李岳 王琪 魏振满,鲁韬. 利他唑酮干混悬剂体内抗菌作用研究[J]. 中国抗生素杂志, 2018, 43(2): 249
作者姓名:朱珍真 陈贞 郎丽巍 王红艳 李岳 王琪 魏振满  鲁韬
摘    要:
目的 研究利他唑酮(LT-01)干混悬剂对败血症和急性肺炎小鼠的体内抗菌作用。方法 以耐万古霉素屎肠球菌(vanomycin-resistant enterococci, VRE)感染败血症和耐甲氧西林金黄色葡萄球菌(methicillin resistant Staphylococcus aureus, MRSA)/青霉素不敏感的肺炎链球菌(penicillin nonsusceptible Streptococcus pneumoniae, PNSSP)感染急性肺炎小鼠为动物模型,灌胃给与LT-01干混悬剂及利奈唑胺片,比较两药对感染小鼠的保护作用,以及对肺炎小鼠肺部活菌清除作用。结果 LT-01干混悬剂对VRE感染小鼠败血症模型以及MRSA感染小鼠急性肺炎模型的ED50分别为4.441和9.550mg/kg,略优于市售利奈唑胺片(ED50分别为6.656和13.843mg/kg);对亚致死量的MRSA和PNSSP感染小鼠急性肺炎模型的24h肺部活菌清除效果与利奈唑胺片相似或略低,但48h的细菌清除效果优于利奈唑胺。结论 实验结果表明LT-01干混悬剂对革兰阳性球菌有很好的抗菌作用,提示LT-01是一种可用于临床治疗耐药革兰阳性球菌感染的药物,值得进一步开发研究。

关 键 词:利他唑酮  利奈唑胺  急性肺炎模型  败血症模型  耐药革兰阳性球菌
  

Studies on the antibacterial activity in vivo of litazolid dry suspension#br#
Abstract:
Objective To study the antibacterial effect in vivo of litazolid (LT-01) dry suspension in models of systemic infections and acute pneumonia. Methods We set up a systemic infection model caused by vanomycin-resistant enterococci (VRE) and pneumonia models produced by intranasal inoculation of methicillin resistant Staphylococcus aureus (MRSA) and penicillin nonsusceptible Streptococcus pneumoniae (PNSSP). Both litazolid and linezolid were administered orally. After the administration, we compared the survival number of mice among each group, and we also compared the bacterial clearance in the lungs among each group. Results In the systemic infection model caused by VRE and pneumonia models produced by MRSA, the 50% effective doses (ED50) of LT-01 were 4.441 and 9.550mg/kg, which were slightly better than linezolid (the ED50 of linezolid were 6.656 and 13.843mg/kg).In acute pneumonia models caused by sub lethal dose of MRSA/PNSSP, the bacterial clearance effects of LT-01 in the lungs was similar to or slightly lower than linezolid at 24h after administration. At 48h, however, the clearance effects of LT-01 was better than that of linezolid. Conclusion The experimental results showed that LT-01 had a good antibacterial effect on Gram-positive bacteria, suggesting that LT-01 was a new drug that can be used in the clinical treatment of infections caused by drug resistant Gram-positive bacteria, which was worthy of further
Keywords: Litazolid  Linezolid  Acute pneumonia model  Systemic infection model  Resistant Gram-positive bacteria   
点击此处可从《中国抗生素杂志》浏览原始摘要信息
点击此处可从《中国抗生素杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号